Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of a Bilateral Single Subretinal Injection of rAAV.hCNGA3 in Adult and Minor Patients With CNGA3-linked Achromatopsia Investigated in a Randomized, Wait List Controlled, Observer-masked Trial
Conditions
Interventions
rAAV.hCNGA3
Locations
1
Germany
University Hospital Tuebingen, Center for Ophthalmology
Tübingen, Germany
Start Date
November 1, 2015
Primary Completion Date
June 1, 2027
Completion Date
June 1, 2027
Last Updated
April 18, 2024
Lead Sponsor
STZ eyetrial
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions